Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05089916 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study

Study acronym: ROSE
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated January 14, 2026 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Enrollment target: estimated 40 to confirmed 42 Completion date: Dec 2026 to Mar 2027v10 Show 1 more changeShow less
    • Completion date: Dec 2026 to Mar 2027
  2. Trial status: Recruiting to Active, Not Recruiting Primary completion date: Dec 2025 to Mar 2026 · Site details revisedv9 Show 2 more changesShow less
    • Primary completion date: Dec 2025 to Mar 2026
    • Site details revised
  3. Re-verified, no change to tracked fieldsv8
  4. Enrollment target: 60 to 40v7
  5. Primary completion date: Sep 2025 to Dec 2025 Completion date: Sep 2026 to Dec 2026 · Eligibility criteria expanded, about 113 wordsv6 Show 2 more changesShow less
    • Completion date: Sep 2026 to Dec 2026
    • Eligibility criteria expanded, about 113 words

    See this version in full on ClinicalTrials.gov ↗

Show 4 earlier versionsHide 4 earlier versions
  1. Site contact updatedv5
  2. Primary completion date: Mar 2026 to Sep 2025v4
  3. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date changed from estimate of Dec 2021 to Jan 20, 2022 · Eligibility criteria expanded, about 18 words · 1 morev3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2021 to Jan 20, 2022
    • Eligibility criteria expanded, about 18 words
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  4. Primary endpoint revised Study arms: 0 to 1v2 Show 1 more changeShow less
    • Study arms: 0 to 1

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study Objectives are: To assess the safety of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease by assessment of grade 3-5 AEs during and after concomitant osimertinib and irradiation of tumor sites. To assess the efficacy of osimertinib treatment continuation during irradiation therapy for palliation or oligoprogressive disease. To investigate Quality of Life during and after irradiation therapy and concomitant osimertinib.
Trial Details
NCT Number NCT05089916
Lead Sponsor AIO-Studien-gGmbH
Collaborators: AstraZeneca
Conditions NSCLC, EGFR Positive Non-small Cell Lung Cancer, Oligoprogression
Enrollment 42 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov